nature portfolio

Corresponding author(s):	Lei Zhang and Xihui Shen			
Last updated by author(s):	Nov 5, 2023			

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

~ .				
St	at	TS:	tı،	\sim

n/a	Confirmed
	$oxed{x}$ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	🕱 A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
x	A description of all covariates tested
	🕱 A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
x	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
x	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
x	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
1	Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

TA NANO-ITC SV microcalorimeter, ITCRun software v3.80, Tanon 5200Multi Chemiluminescent Imaging System, AB SCIEX QTRAP 6500+ LC-MS/MS System, AKTA Purifier FPLC system, LightCycler 96 thermocycler, Biotek Epoch Microplate Reader

Data analysis

Microsoft Excel 2019, Prism Graphpad 8.0, Primer premier 5.0, Tanon gel analysis 2.30, NanoAnalyze_3.4, POCASA v1.1, AutoDock Vina v1.1.2, PyMOL v2.5.2, LigPlot+ v2.2.4, ImageJ v1.52a, Bowtie v2.3.2, FeatureCounts v1.6.0, DESeq2 R package v1.12.4

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The protein 3D coordinate data used in this study are available in the PDB database under the accession code 2L93 (https://www.rcsb.org/structure/2L93). The structure of c-di-GMP used in this study is available from the crystal structure of the c-di-GMP-MapZ complex in the PDB database under the accession code 2L74 (https://www.rcsb.org/structure/2L74). The S. Typhimurium LT2 reference genome used in this study is available in the NCBI nucleotide database under the

accession numbers NC_003197 (https://www.ncbi.nlm.nih.gov/nuccore/NC_003197) and NC_003277 (https://www.ncbi.nlm.nih.gov/nuccore/NC_003277). The RNA-seq data generated in this study have been deposited in the NCBI BioProject database under the accession number PRJNA975738 (https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA975738). All the other data that support the findings of this study are available within the paper and its Supplementary Information and Supplementary Data. The source data underlying Figs. 1, 2a–c, f, 3, 4 and 5c–e and Supplementary Figs. 1–7, 9a, 10b and 11–17 are provided as a Source Data file.

Research	h invo	lving	human i	partici	nants. :	their d	data, or	biol	ogical	materia	l
researe	111110	٥٠٠٠٠	Halliali	par cier	parres,	ci i Ci i	aaca, or	0101	OBICAI	maccina	٠.

X Plants

	ut studies with human participants or human data. See also policy information about sex, gender (identity/presentation), and race, ethnicity and racism.
Reporting on sex and go	nder N/A
Reporting on race, ethr other socially relevant §	
Population characterist	cs N/A
Recruitment	N/A
Ethics oversight	N/A
Note that full information	on the approval of the study protocol must also be provided in the manuscript.
Field-spec	fic reporting
Please select the one b	elow that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
X Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences
or a reference copy of the d	ocument with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf
ifo soiono	os study dosign
_ne scienc	es study design
All studies must disclos	e on these points even when the disclosure is negative.
Co	nple sizes were determined without statistical measures, but based on widely used sizes in relevant publications (Zhang et al. Nat. nmun. 2020, 11:5371; Gan et al. Nat Microbiol. 2019, 4:134-143; Lin et al. Nat. Commun. 2017, 8:14888; Zheng et al. Mol. Microbiol. 2013 403-419; Li et al. Nat. Commun. 2022, 13:6684) to ensure that it will be appropriate for statistical analysis.
Data exclusions No	data were excluded from the analyses.
Replication	experiments were performed for at least 3 times. All the attempts at replication were successful.
	experimental groups or control groups were subjectively chosen and there are no covariates to control for as experiments were done in genic strains. No experiments required randomization.
Blinding	estigators were not blinded during data collection or analysis since there was not group allocation.
)	
	for specific materials, systems and methods
	om authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.
Materials & exper	mental systems Methods
n/a Involved in the st	
Antibodies	ChIP-seq
Eukaryotic cell	
	mind archaeology MRI-based neuroimaging
Animals and ot Clinical data	IEI OI BAIII 21112
Dual use resea	ch of concern
Dual use lesea	an or concern

Antibodies

Antibodies used

Rabbit anti-ICDH is a kind gift from Dr. ZQ. Luo at Purdue University and was described in: Xu, L. et al. PLoS Pathog. 6, e1000822 (2010). Purified ICDH was used to inject rabbits and the antisera were affinity purified using Protein A Sepharose (GE Healthcare). Commercial antibodies used are listed as below: Mouse anti-VSVG (Abways, Shanghai, China, clone 4A10, cat# AB0063); Mouse anti-FLAG (Abways, Shanghai, China, clone 5C3, cat# AB0028); Mouse anti-His (Abways, Shanghai, China, clone 3B5, cat# AB0002); Streptavidin-horseradish peroxidase (Thermo Scientific, cat# 21126); Goat anti-Mouse horseradish peroxidase-conjugated secondary antibodies (DIYIBIO, China, cat# DY60203); Goat anti-Rabbit horseradish peroxidase-conjugated secondary antibodies (DIYIBIO, China, cat# DY60202).

Validation

The homemade antibody Rabbit anti-ICDH has been validated by our lab using appropriate positive and negative controls in previous studies (Li et al. Nat. Commun. 2022, 13:6684; Zhu et al., Proc. Natl. Acad. Sci. U S A. 2021, 118(42):e2103526118).

The antibodies obtained commercially have been validated by the manufacturers.

Antibody, catalogue number, manufacturer information for commercial antibodies:

- -Mouse anti-VSVG (Abways, Shanghai, China, cat# AB0063): http://www.abways.com/showproduct.asp?cid=AB0063
- -Mouse anti-FLAG (Abways, Shanghai, China, cat# AB0028): http://www.abways.com/showproduct.asp?cid=AB0028
- -Mouse anti-His (Abways, Shanghai, China, cat# AB0002): http://www.abways.com/showproduct.asp?cid=AB0002
- $Strep tavid in + horser a dish peroxidase \ (Thermo Scientific, cat \# 21126): https://www.thermofisher.cn/order/catalog/product/21126$
- -Goat anti-Mouse horseradish peroxidase-conjugated secondary antibodies (DIYIBIO, China, cat# DY60203): https://www.deeyeebio.com/list_51/243.html
- -Goat anti-Rabbit horseradish peroxidase-conjugated secondary antibodies (DIYIBIO, China, cat# DY60202): https://www.deeyeebio.com/list_51/242.html